MATTHEW ADAMS: Open Payments
NPI 1376318238 · FRISCO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,081 in 51 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $20 · 2025 $1,081
Food & beverage: $1,081
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 16 | $312 |
| Alkermes, Inc. | 1 | $122 |
| Lundbeck LLC | 5 | $109 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $99 |
| Janssen Pharmaceuticals, Inc | 5 | $88 |
| E.R. Squibb & Sons, L.L.C. | 5 | $85 |
| Axsome Therapeutics, Inc. | 3 | $73 |
| GlaxoSmithKline, LLC. | 3 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $54 |
| ABBVIE INC. | 2 | $40 |
Products named: FANAPT, REXULTI, LYBALVI, CAPLYTA, SPRAVATO, COBENFY, Auvelity, NUCALA.
Industry payments across TX — which companies pay providers there.
